Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Cutaneous Melanoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
8 drugs · 42 active trials
0 drugs · 0 active trials
no drug at this stage
1 drug · 11 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ipilimumab | Approved | Phase 3 | 11 | 3 | 3 | 25 | 1 | US | Mar 25, 2011 | Dec 28, 2010 |
| Nivolumab | Phase 3 | Phase 3 | 18 | 8 | 1 | 33 | 0 | — | — | Aug 28, 2013 |
| Pembrolizumab | Phase 3 | Phase 3 | 15 | 6 | 3 | 36 | 0 | — | — | Feb 5, 2015 |
| Aldesleukin | Phase 3 | Phase 3 | 4 | 1 | 1 | 13 | 0 | — | — | 1999-12 |
| Camrelizumab | Phase 3 | Phase 3 | 2 | 2 | 1 | 2 | 0 | — | — | Sep 13, 2022 |
| Sorafenib Tosylate | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | 2005-06 |
| Paclitaxel | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | 2005-06 |
| Immunotherapy | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Aug 6, 2025 |
| Carboplatin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2005-06 |
| Binimetinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Dec 9, 2016 |
| Encorafenib | Phase 2 | Phase 2 | 4 | 2 | 0 | 5 | 0 | — | — | Dec 9, 2016 |
| Cyclophosphamide | Phase 2 | Phase 2 | 3 | 2 | 0 | 10 | 0 | — | — | Apr 15, 2011 |
| Fludarabine | Phase 2 | Phase 2 | 3 | 2 | 0 | 8 | 0 | — | — | Apr 15, 2011 |
| Dabrafenib | Phase 2 | Phase 2 | 3 | 0 | 0 | 6 | 0 | — | — | Aug 28, 2013 |
| Trametinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 6 | 0 | — | — | Aug 28, 2013 |
| Bevacizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 6 | 0 | — | — | 2001-11 |
| Atezolizumab | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 6, 2020 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jun 5, 2018 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 20, 2013 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2010-08 |
| Avelumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 4, 2022 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 24, 2023 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 28, 2019 |
| Dinaciclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2009 |
| Doxorubicin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 30, 2023 |
| Eribulin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 30, 2023 |
| Ipilimumab/Nivolumab Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 9, 2026 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-01 |
| Cisplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-08 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 16, 2016 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-04 |
| Nilotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 23, 2009 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 18, 2011 |
| Aspirin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 19, 2018 |
| Cabozantinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 8, 2022 |
| Capmatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 26, 2015 |
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 26, 2015 |
| Dacarbazine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-01 |
| Denosumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 10, 2018 |
| Entrectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 26, 2015 |
| Imatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-07 |
| Metformin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-05 |
| Olaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 4, 2022 |
| Regorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 26, 2015 |
| Rituximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-03 |
| Selumetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-03 |
| Sunitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-08 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-01 |
| Uprosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 8, 2013 |
| Vinblastine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-08 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.